BR112022020628A2 - Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe - Google Patents
Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibeInfo
- Publication number
- BR112022020628A2 BR112022020628A2 BR112022020628A BR112022020628A BR112022020628A2 BR 112022020628 A2 BR112022020628 A2 BR 112022020628A2 BR 112022020628 A BR112022020628 A BR 112022020628A BR 112022020628 A BR112022020628 A BR 112022020628A BR 112022020628 A2 BR112022020628 A2 BR 112022020628A2
- Authority
- BR
- Brazil
- Prior art keywords
- actriib
- methods
- anemia
- treatment
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title abstract 3
- 208000007502 anemia Diseases 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 3
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 abstract 2
- 229950003487 fedratinib Drugs 0.000 abstract 2
- 102000005606 Activins Human genes 0.000 abstract 1
- 108010059616 Activins Proteins 0.000 abstract 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 1
- 108010054147 Hemoglobins Proteins 0.000 abstract 1
- 239000000488 activin Substances 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009400P | 2020-04-13 | 2020-04-13 | |
| PCT/US2021/026816 WO2021211418A1 (en) | 2020-04-13 | 2021-04-12 | Methods for treating anemia using an actriib ligand trap and fedratinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020628A2 true BR112022020628A2 (pt) | 2022-11-29 |
Family
ID=78085002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020628A BR112022020628A2 (pt) | 2020-04-13 | 2021-04-12 | Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181690A1 (https=) |
| EP (1) | EP4135736A4 (https=) |
| JP (1) | JP2023523568A (https=) |
| KR (1) | KR20230003502A (https=) |
| CN (1) | CN115427056A (https=) |
| AU (1) | AU2021256419A1 (https=) |
| BR (1) | BR112022020628A2 (https=) |
| IL (1) | IL297258A (https=) |
| MX (1) | MX2022012610A (https=) |
| WO (1) | WO2021211418A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| CA2983440C (en) * | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| US20180125928A1 (en) * | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| MA45811A (fr) * | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
| WO2018053142A2 (en) * | 2016-09-14 | 2018-03-22 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| PL3638243T3 (pl) * | 2017-06-14 | 2025-02-10 | Celgene Corporation | Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości |
| WO2020041466A1 (en) * | 2018-08-21 | 2020-02-27 | Sierra Oncology, Inc. | Platelet count-agnostic methods of treating myelofibrosis |
| KR20250134004A (ko) * | 2018-09-25 | 2025-09-09 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
-
2021
- 2021-04-12 US US17/995,915 patent/US20230181690A1/en active Pending
- 2021-04-12 JP JP2022562528A patent/JP2023523568A/ja active Pending
- 2021-04-12 BR BR112022020628A patent/BR112022020628A2/pt unknown
- 2021-04-12 KR KR1020227039230A patent/KR20230003502A/ko active Pending
- 2021-04-12 MX MX2022012610A patent/MX2022012610A/es unknown
- 2021-04-12 WO PCT/US2021/026816 patent/WO2021211418A1/en not_active Ceased
- 2021-04-12 EP EP21787716.6A patent/EP4135736A4/en active Pending
- 2021-04-12 CN CN202180028593.0A patent/CN115427056A/zh active Pending
- 2021-04-12 IL IL297258A patent/IL297258A/en unknown
- 2021-04-12 AU AU2021256419A patent/AU2021256419A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4135736A1 (en) | 2023-02-22 |
| CN115427056A (zh) | 2022-12-02 |
| EP4135736A4 (en) | 2024-06-26 |
| WO2021211418A1 (en) | 2021-10-21 |
| JP2023523568A (ja) | 2023-06-06 |
| US20230181690A1 (en) | 2023-06-15 |
| KR20230003502A (ko) | 2023-01-06 |
| IL297258A (en) | 2022-12-01 |
| MX2022012610A (es) | 2022-11-07 |
| AU2021256419A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cavaletti | Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we know | |
| Shin et al. | Efficacy of perioperative intravenous iron therapy for transfusion in orthopedic surgery: a systematic review and meta-analysis | |
| Zagari et al. | Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study | |
| BR112022020628A2 (pt) | Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe | |
| Macdougall et al. | Conference Participants. Iron management in chronic kidney disease: conclusions from a" kidney disease: improving global outcomes"(KDIGO) controversies conference | |
| BR112021024310A2 (pt) | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus | |
| BR112019003989A2 (pt) | métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado | |
| BR112017023904A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| BR112017006299A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
| BR112023001956A2 (pt) | Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer | |
| BR112016009669A8 (pt) | produtos farmacêuticos, método para tratar câncer e uso de um composto | |
| BR112015000660A8 (pt) | uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car. | |
| BR112018011803A2 (pt) | método e mecanismo para a administração de gases incluindo óxido nítrico | |
| NO20090623L (no) | Forbindelser for behandling av proliferative lidelser | |
| BR112017015123A2 (pt) | derivados de indol como inibidores da replicação viral do dengue | |
| BR112017006113A2 (pt) | combinações sinérgicas de auristatina | |
| BR112017006708A2 (pt) | indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue | |
| BR112018068676A2 (pt) | derivados de indol substituídos como inibidores da replicação viral do dengue | |
| MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| CY1111369T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη | |
| BR112021008582A8 (pt) | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer | |
| BR112022023928A2 (pt) | Uso de canabidiol para o tratamento do transtorno do espectro autista | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo |